Viral Vector based Therapeutics
Genvira specializes in viral vector engineering. Our expertise is focused on designing, constructing and characterizing RNA/DNA viral vectors that are non-pathogenic, genetically stable, optimized for immunogenicity and transduction efficiency, scalable from a manufacturing perspective. Our platform underpins pipeline and partnered programs in:
- Cancer Immunotherapy
- Gene therapy
- Vaccines
Cancer Immunotherapy & Gene Therapy
Our bioengineered viruses are built to deliver genes of interest to targeted mammalian cells and tissues, providing new cellular instructions to modulate diseases including cancers and rare disease. Our development engine integrates potency, durability, and immunogenicity assays to rank candidates, de-risk translation, and advance the most promising vectors into preclinical and co-development pathways.
Vaccines
We are advancing vector-enabled cancer vaccines and co-developing programs with partners to move rapidly from discovery to IND. Our platform encodes tumor neoantigens and immune modulators into optimized viral vectors to drive durable, tumor-specific T-cell responses.
